Journal ArticleDOI
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048) : a randomised, open-label, phase 3 study
Barbara Burtness,Kevin J. Harrington,Richard Greil,Denis Soulières,Makoto Tahara,Gilberto de Castro,Amanda Psyrri,Neus Baste,Prakash Neupane,Åse Bratland,Thorsten Fuereder,Brett G.M. Hughes,Ricard Mesia,Nuttapong Ngamphaiboon,Tamara Rordorf,Wan Zamaniah Wan Ishak,Ruey-Long Hong,René González Mendoza,Ananya Roy,Yayan Zhang,Burak Gumuscu,Jonathan D. Cheng,Fan Jin,Danny Rischin,Danny Rischin,Guillermo Lerzo,Marcelo Tatangelo,Mirta Varela,J. J. Zarba,Michael Boyer,Hui K Gan,Bo Gao,Brett Hughes,Girish Mallesara,Anne W. Taylor,Martin Burian,Carlos H. Barrios,Dalvaro Oliveira de Castro Junior,Gilberto de Castro,Fabio Franke,Gustavo Girotto,Iane Pinto Figueiredo Lima,Ulisses Ribaldo Nicolau,Gustavo Dix Junqueira Pinto,Lucas Vieira dos Santos,Ana Paula Victorino,Neil Chua,Felix Couture,Richard Gregg,Aaron R. Hansen,John Hilton,Joy McCarthy,Rodrigo Ascui,Pablo Gonzalez,Luis Villanueva,Marco Torregroza,Angela Zambrano,Petra Holeckova,Zdenek Kral,Bohuslav Melichar,Jana Prausova,Milan Vosmik,Maria Andersen,Niels Gyldenkerne,Hannes Jurgens,Kadri Putnik,Petri Reinikainen,Viktor Gruenwald,Simon Laban,Gerasimos Aravantinos,Ioannis Boukovinas,Vassilis Georgoulias,Dora Kwong,Yousuf Al-Farhat,Tibor Csoszi,Jozsef Erfan,Geza Horvai,Laszlo Landherr,Éva Remenár,Agnes Ruzsa,Judit Szota,Salem Billan,Iris Gluck,Orit Gutfeld,Aron Popovtzer,Marco Benasso,Simona Bui,Vittorio Ferrari,Lisa Licitra,Franco Nolè,Takashi Fujii,Yasushi Fujimoto,Nobuhiro Hanai,Hiroki Hara,Koji Matsumoto,Kenji Mitsugi,Nobuya Monden,Masahiro Nakayama,Kenji Okami,Nobuhiko Oridate,Kiyoto Shiga,Yasushi Shimizu,Masashi Sugasawa,Masanobu Takahashi,Shunji Takahashi,Kaoru Tanaka,Tsutomu Ueda,Hironori Yamaguchi,Tomoko Yamazaki,Ryuji Yasumatsu,Tomoya Yokota,Tomokazu Yoshizaki,Iveta Kudaba,Zinaida Stara,Soon Keat Cheah,Jose Aguilar Ponce,Carlos Hernandez Hernandez,Francisco Medina Soto,Jan Buter,Ann Hoeben,Sjoukje F. Oosting,Karijn P M Suijkerbuijk,Aase Bratland,Marianne Brydoey,Renzo Alvarez,Luis Mas,Priscilla Caguioa,John Querol,Eugenio Emmanuel Regala,Maria Belen Tamayo,Ellie May Villegas,Andrzej Kawecki,Andrey Karpenko,Arkadiy Klochikhin,Alexey Smolin,Oleg Zarubenkov,Boon Cher Goh,Graham Cohen,Johanna du Toit,Christa Jordaan,Gregory Landers,Paul Ruff,Waldemar Szpak,Neonyana Tabane,Irene Brana,Lara Carmen Iglesias Docampo,Javier Lavernia,Edvard Abel,Valentina Muratidu,Niels Nielsen,Valerie Cristina,Sacha Rothschild,Hung Ming Wang,Muh Hwa Yang,Su Peng Yeh,Chia Jui Yen,Nopadol Soparattanapaisarn,Virote Sriuranpong,Sercan Aksoy,Irfan Cicin,Meltem Ekenel,Hakan Harputluoglu,Ozgur Ozyilkan,Kevin J. Harrington,Sanjiv S. Agarwala,Haythem Ali,Robert Alter,Daniel Anderson,Justine Bruce,Nicholas Campbell,Miguel Conde,John F. Deeken,William Edenfield,Lawrence E. Feldman,Elizabeth Gaughan,Basem Goueli,Balazs Halmos,Upendra P. Hegde,Brian Hunis,Robert Jotte,Anand B. Karnad,Saad A. Khan,Noel Laudi,Douglas Laux,Danko Martincic,Steven McCune,Dean McGaughey,Krzysztof Misiukiewicz,Deborah Mulford,Eric Nadler,Johannes Nunnink,James Ohr,Meaghan O'Malley,Brian Patson,Doru Paul,Elizabeta Popa,Steven Francis Powell,Rebecca Redman,Vincent Rella,Chaio Rocha Lima,Abirami Sivapiragasam,Yungpo Su,Ammar Sukari,Stuart Wong,Emrullah Yilmaz,Jeffrey Yorio +205 more
Reads0
Chats0
TLDR
A randomised, phase 3 study of participants with untreated locally incurable recurrent or metastatic HNSCC done at 200 sites in 37 countries finds that pembrolizumab alone improved overall survival and progression-free survival and cetuximab with chemotherapy improved Overall survival in the total population.About:
This article is published in The Lancet.The article was published on 2019-11-23. It has received 1490 citations till now. The article focuses on the topics: Pembrolizumab & Population.read more
Citations
More filters
Journal ArticleDOI
Head and neck squamous cell carcinoma
Daniel Johnson,Barbara Burtness,C. René Leemans,Vivian Wai Yan Lui,Julie E. Bauman,Jennifer R. Grandis +5 more
TL;DR: This Primer provides an overview of the epidemiology, pathogenesis and treatment of HNSCCs of different aetiologies and the effects of the cancer and its treatment on patient quality of life.
Journal ArticleDOI
Head and Neck Cancers, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology.
David G. Pfister,Sharon A. Spencer,David J. Adelstein,Douglas Adkins,Yoshimi Anzai,David M. Brizel,Justine Yang Bruce,Paul M. Busse,Jimmy J. Caudell,Anthony J. Cmelak,A. Dimitrios Colevas,David W. Eisele,Moon Fenton,Robert L. Foote,Thomas J. Galloway,Maura L. Gillison,Robert I. Haddad,Wesley L. Hicks,Ying J. Hitchcock,Antonio Jimeno,Debra S. Leizman,Ellie Maghami,Loren K. Mell,Bharat B. Mittal,Harlan A. Pinto,John A. Ridge,James W. Rocco,Cristina P. Rodriguez,Jatin P. Shah,Randal S. Weber,Gregory S. Weinstein,Matthew E. Witek,Frank Worden,Sue S. Yom,Weining Zhen,Jennifer L. Burns,Susan Darlow +36 more
TL;DR: The NCCN Guidelines for Head and Neck Cancers as mentioned in this paper describe supportive care recommendations for patients with H&N cancers and the rationale supporting a new section on imaging recommendations for head and neck cancers.
Journal ArticleDOI
PD-L1 as a biomarker of response to immune-checkpoint inhibitors
Deborah B. Doroshow,Sheena Bhalla,Mary Beth Beasley,Lynette M. Sholl,Keith M. Kerr,Sacha Gnjatic,Ignacio I. Wistuba,David L. Rimm,Ming-Sound Tsao,Fred R. Hirsch +9 more
TL;DR: In this paper, the authors describe the current role of PD-L1 immunohistochemistry assays used to inform the selection of patients to receive antiPD-1 or anti-PD-L 1 antibodies, discuss the various technical and clinical challenges associated with these assays, including regulatory issues, and provide some perspective on how to optimize PDL1 as a selection biomarker for the future treatment of patients with solid tumours.
Journal ArticleDOI
Acquired Resistance to Immune Checkpoint Inhibitors.
TL;DR: The barriers to progress and emerging clinical reports interrogating acquired resistance are examined with the goal to facilitate efforts to overcome acquired resistance to ICIs in the future.
Journal ArticleDOI
Immune Landscape of Viral- and Carcinogen-Driven Head and Neck Cancer
Anthony R. Cillo,Cornelius H.L. Kurten,Cornelius H.L. Kurten,Tracy Tabib,Zengbiao Qi,Sayali Onkar,Ting Wang,Angen Liu,Umamaheswar Duvvuri,Seungwon Kim,Ryan J. Soose,Steffi Oesterreich,Wei Chen,Robert Lafyatis,Tullia C. Bruno,Robert L. Ferris,Dario A. A. Vignali +16 more
TL;DR: A gene expression signature associated with CD4+ T follicular helper cells that is associated with longer progression-free survival in HNSCC patients is defined and provided a resource for the further study of the impact of immune cells on viral- and carcinogen-induced cancers.
References
More filters
Journal ArticleDOI
Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
Hossein Borghaei,Luis Paz-Ares,Leora Horn,D. R. Spigel,M. Steins,Neal Ready,L.Q. Chow,Everett E. Vokes,Enriqueta Felip,Esther Holgado,F. Barlesi,M. Kohlhufl,Oscar Arrieta,Marco Angelo Burgio,J. Fayette,H. Lena,Elena Poddubskaya,David E. Gerber,Scott N. Gettinger,Charles M. Rudin,Naiyer A. Rizvi,L. Crina,G. R. Blumenschein,Scott J. Antonia,C. Dorange,C. T. Harbison,F. Graf Finckenstein,Julie R. Brahmer +27 more
TL;DR: Nivolumab was associated with even greater efficacy than docetaxel across all end points in subgroups defined according to prespecified levels of tumor-membrane expression (≥1, ≥5%, and ≥10%) of the PD-1 ligand.
Journal ArticleDOI
Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer
Julie R. Brahmer,Karen L. Reckamp,Paul Baas,Lucio Crinò,Wilfried Eberhardt,Elena Poddubskaya,Scott J. Antonia,Adam Pluzanski,Everett E. Vokes,Esther Holgado,David M. Waterhouse,Neal Ready,Justin F. Gainor,Osvaldo Arén Frontera,Libor Havel,Martin Steins,Marina Chiara Garassino,Joachim G.J.V. Aerts,Manuel Domine,Luis Paz-Ares,Martin Reck,Christine Baudelet,Christopher T. Harbison,Brian Lestini,David R. Spigel +24 more
TL;DR: Among patients with advanced, previously treated squamous-cell NSCLC, overall survival, response rate, and progression-free survival were significantly better with nivolumab than with docetaxel, regardless of PD-L1 expression level.
Journal ArticleDOI
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial.
Roy S. Herbst,Paul Baas,Dong Wan Kim,Enriqueta Felip,Jose Luis Perez-Gracia,Ji Youn Han,Julian R. Molina,Joo Hang Kim,Catherine Dubos Arvis,Myung-Ju Ahn,Margarita Majem,Mary J. Fidler,Gilberto de Castro,Marcelo Garrido,Gregory M. Lubiniecki,Yue Shentu,Ellie Im,Marisa Dolled-Filhart,Edward B. Garon +18 more
TL;DR: In this article, the authors evaluated the efficacy of pembrolizumab for patients with previously treated, PD-L1-positive, advanced non-small-cell lung cancer.
Journal ArticleDOI
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
Robert J. Motzer,Bernard Escudier,David F. McDermott,Saby George,Hans J. Hammers,Sandhya Srinivas,Scott S. Tykodi,Jeffrey A. Sosman,Giuseppe Procopio,Elizabeth R. Plimack,Daniel Castellano,Toni K. Choueiri,Howard Gurney,Frede Donskov,Petri Bono,John Wagstaff,Thomas Gauler,Takeshi Ueda,Yoshihiko Tomita,Fabio A.B. Schutz,Christian Kollmannsberger,James Larkin,Alain Ravaud,Jason S. Simon,Li-an Xu,Ian M. Waxman,Padmanee Sharma +26 more
TL;DR: Overall survival was longer and fewer grade 3 or 4 adverse events occurred with nivolumab than with everolimus among patients with previously treated advanced renal-cell carcinoma.
Journal ArticleDOI
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
Robert L. Ferris,George R. Blumenschein,Jérôme Fayette,Joël Guigay,A. Dimitrios Colevas,Lisa Licitra,Kevin J. Harrington,Stefan Kasper,Everett E. Vokes,Caroline Even,Francis P. Worden,Nabil F. Saba,Lara Carmen Iglesias Docampo,Robert I. Haddad,Tamara Rordorf,Naomi Kiyota,Makoto Tahara,Manish Monga,Mark Lynch,William J. Geese,Justin Kopit,James W. Shaw,Maura L. Gillison +22 more
TL;DR: Among patients with platinum-refractory, recurrent squamous-cell carcinoma of the head and neck, treatment with nivolumab resulted in longer overall survival than treatment with standard, single-agent therapy.
Related Papers (5)
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
Robert L. Ferris,George R. Blumenschein,Jérôme Fayette,Joël Guigay,A. Dimitrios Colevas,Lisa Licitra,Kevin J. Harrington,Stefan Kasper,Everett E. Vokes,Caroline Even,Francis P. Worden,Nabil F. Saba,Lara Carmen Iglesias Docampo,Robert I. Haddad,Tamara Rordorf,Naomi Kiyota,Makoto Tahara,Manish Monga,Mark Lynch,William J. Geese,Justin Kopit,James W. Shaw,Maura L. Gillison +22 more
Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer
Comprehensive genomic characterization of head and neck squamous cell carcinomas
Michael S. Lawrence,Carrie Sougnez,Lee Lichtenstein,Kristian Cibulskis,Eric S. Lander,Stacey Gabriel,Gad Getz,Adrian Ally,Miruna Balasundaram,Inanc Birol,Reanne Bowlby,Denise Brooks,Yaron S.N. Butterfield,Rebecca Carlsen,Dean Cheng,Andy Chu,Noreen Dhalla,Ranabir Guin,Robert A. Holt,Steven J.M. Jones,Darlene Lee,Haiyan I. Li,Marco A. Marra,Michael Mayo,Richard A. Moore,Andrew J. Mungall,A. Gordon Robertson,Jacqueline E. Schein,Payal Sipahimalani,Angela Tam,Nina Thiessen,Tina Wong,Alexei Protopopov,Netty Santoso,Semin Lee,Michael Parfenov,Jianhua Zhang,Harshad S. Mahadeshwar,Jiabin Tang,Xiaojia Ren,Sahil Seth,Psalm Haseley,Dong Zeng,Lixing Yang,Andrew Wei Xu,Xingzhi Song,Angeliki Pantazi,Christopher A. Bristow,Angela Hadjipanayis,Jonathan G. Seidman,Lynda Chin,Peter J. Park,Raju Kucherlapati,Rehan Akbani,Tod D. Casasent,Wenbin Liu,Yiling Lu,Gordon B. Mills,Thomas C. Motter,John N. Weinstein,Lixia Diao,Jing Wang,You Hong Fan,Jinze Liu,Kai Wang,J. Todd Auman,Saianand Balu,Thomas Bodenheimer,Elizabeth Buda,D. Neil Hayes,Katherine A. Hoadley,Alan P. Hoyle,Stuart R. Jefferys,Corbin D. Jones,Patrick K. Kimes,Yufeng Liu,James Stephen Marron,Shaowu Meng,Piotr A. Mieczkowski,Lisle E. Mose,Joel S. Parker,Charles M. Perou,Jan F. Prins,Jeffrey Roach,Yan Shi,Janae V. Simons,Darshan Singh,Matthew G. Soloway,Donghui Tan,Umadevi Veluvolu,Vonn Walter,Scot Waring,Matthew D. Wilkerson,Junyuan Wu,Ni Zhao,Andrew D. Cherniack,Peter S. Hammerman,Aaron D. Tward,Chandra Sekhar Pedamallu,Gordon Saksena,Joonil Jung,Akinyemi I. Ojesina,Scott L. Carter,Travis I. Zack,Steven E. Schumacher,Rameen Beroukhim,Samuel S. Freeman,Matthew Meyerson,Juok Cho,Michael S. Noble,Daniel DiCara,Hailei Zhang,David I. Heiman,Nils Gehlenborg,Doug Voet,Pei Lin,Scott Frazer,Petar Stojanov,Yingchun Liu,Lihua Zou,Jaegil Kim,Donna M. Muzny,Harshavardhan Doddapaneni,Christie Kovar,Jeffrey S. Reid,Donna Morton,Yi Han,Walker Hale,Hsu Chao,Kyle Chang,Jennifer Drummond,Richard A. Gibbs,Nipun Kakkar,David A. Wheeler,Liu Xi,Giovanni Ciriello,Marc Ladanyi,William Lee,Ricardo Ramirez,Chris Sander,Ronglai Shen,Rileen Sinha,Nils Weinhold,Barry S. Taylor,B. Arman Aksoy,Gideon Dresdner,Jianjiong Gao,Benjamin Gross,Anders Jacobsen,Boris Reva,Nikolaus Schultz,S. Onur Sumer,Yichao Sun,Timothy A. Chan,Luc G. T. Morris,Joshua M. Stuart,Stephen C. Benz,Sam Ng,Christopher C. Benz,Christina Yau,Stephen B. Baylin,Leslie Cope,Ludmila Danilova,James G. Herman,Moiz S. Bootwalla,Dennis T. Maglinte,Peter W. Laird,Timothy J. Triche,Daniel J. Weisenberger,David Van Den Berg,Nishant Agrawal,Justin A. Bishop,Paul C. Boutros,Jeff Bruce,Lauren Averett Byers,Joseph A. Califano,Thomas E. Carey,Zhong Chen,Hui Cheng,Simion I. Chiosea,Ezra E.W. Cohen,Brenda Diergaarde,Ann Marie Egloff,Adel K. El-Naggar,Robert L. Ferris,Mitchell J. Frederick,Jennifer R. Grandis,Yan Guo,Robert I. Haddad,Thomas M. Harris,Angela B.Y. Hui,J. Jack Lee,Scott M. Lippman,Fei-Fei Liu,Jonathan B. McHugh,Jeffrey N. Myers,Patrick Kwok Shing Ng,Bayardo Perez-Ordonez,Curtis R. Pickering,Michael B. Prystowsky,Marjorie Romkes,Anthony Saleh,Maureen A. Sartor,Raja R. Seethala,Tanguy Y. Seiwert,Han Si,Carter Van Waes,Daryl Waggott,Maciej Wiznerowicz,Wendell G. Yarbrough,Jiexin Zhang,Zhixiang Zuo,Ken Burnett,Daniel Crain,Johanna Gardner,Kevin Lau,David Mallery,Scott Morris,Joseph Paulauskis,Robert Penny,Candace Shelton,Troy Shelton,Mark E. Sherman,Peggy Yena,Aaron D. Black,Jay Bowen,Jessica Frick,Julie M. Gastier-Foster,Hollie A. Harper,Kristen M. Leraas,Tara M. Lichtenberg,Nilsa C. Ramirez,Lisa Wise,Erik Zmuda,Julien Baboud,Mark A. Jensen,Ari B. Kahn,Todd Pihl,David Pot,Deepak Srinivasan,Jessica Walton,Yunhu Wan,Robert A. Burton,Tanja Davidsen,John A. Demchok,Greg Eley,Martin L. Ferguson,Kenna R. Mills Shaw,Bradley A. Ozenberger,Margi Sheth,Heidi J. Sofia,Roy Tarnuzzer,Zhining Wang,Liming Yang,Jean C. Zenklusen,Charles Saller,Katherine Tarvin,Chu Chen,Roni J. Bollag,Paul M. Weinberger,Wojciech Golusiński,Paweł Golusiński,Matthew Ibbs,Konstanty Korski,Andrzej Mackiewicz,Wiktoria Maria Suchorska,Bartosz Szybiak,Erin Curley,Christina Beard,Colleen Mitchell,George E. Sandusky,Julie Ahn,Zubair Khan,Jonathan C. Irish,John Waldron,William N. William,Sophie C. Egea,Carmen Gomez-Fernandez,Lynn M. Herbert,Carol R. Bradford,Douglas B. Chepeha,Andrea Haddad,Tamara R. Jones,Christine M. Komarck,Mayya Malakh,Jeffrey S. Moyer,Ariane Nguyen,Lisa A. Peterson,Mark E. Prince,Laura S. Rozek,Evan G. Taylor,Heather M. Walline,Gregory T. Wolf,Lori Boice,Bhishamjit S. Chera,William K. Funkhouser,Margaret L. Gulley,Trevor Hackman,Michele C. Hayward,Mei Huang,W. Kimryn Rathmell,Ashley H. Salazar,William W. Shockley,Carol G. Shores,Leigh B. Thorne,Mark C. Weissler,Sylvia Wrenn,Adam M. Zanation,Brandee T. Brown,Michelle Q. Pham +309 more